Fibroblast growth factor (FGF) 21, a unique, largely liver-derived endocrine member of the FGF superfamily, is often thought of as a fasting factor owing to its induction in rodents during starvation. However, FGF21 is not increased by fasting for periods of ,7 days in humans; instead, it rises sharply after acute alcohol and sugar intake and also after several days of overfeeding, suggesting another role in states of positive energy balance. Recent studies suggest that in the postingestive state, FGF21 may regulate energy intake and discourage consumption of alcohol and sugars, most likely through effector circuits in the central nervous system. FGF21 also increases fat oxidation in the liver, improves markers of insulin sensitivity, and stimulates adiponectin production. Thus, in primates, FGF21 may defend against hepatic nutrient overload by promoting adaptations that reduce ectopic lipid storage, including inhibiting sugar and alcohol appetite and promoting lipid sequestration in adipose tissue. (Endocrinology 159: 1966(Endocrinology 159: -1970(Endocrinology 159: , 2018 I n 2000, FGF21 was cloned by the Itoh laboratory (1), and 5 years later, fibroblast growth factor (FGF) 21 was identified as a potent antidiabetic agent in vitro and in rodents by Kharitonenkov et al. (2) at Eli Lilly. Since then, an impressive amount of basic research has been done in this area, leading to an appreciation of the complex actions of FGF21 in multiple tissues (3-5), as well as to the common view among metabolism researchers that FGF21 is a fasting hormone with beneficial effects on glucose and lipid metabolism, energy expenditure, and body weight.
I n 2000, FGF21 was cloned by the Itoh laboratory (1), and 5 years later, fibroblast growth factor (FGF) 21 was identified as a potent antidiabetic agent in vitro and in rodents by Kharitonenkov et al. (2) at Eli Lilly. Since then, an impressive amount of basic research has been done in this area, leading to an appreciation of the complex actions of FGF21 in multiple tissues (3) (4) (5) , as well as to the common view among metabolism researchers that FGF21 is a fasting hormone with beneficial effects on glucose and lipid metabolism, energy expenditure, and body weight.
In humans, however, a puzzle lingers. With the exception of extremely long fasts (.7 days) (6, 7) , the metabolic stimuli that increase circulating FGF21 are often associated with the fed state or other states of positive energy balance (7) (8) (9) (10) (11) (12) (13) . However, the biological significance of these postingestive changes in FGF21 remains poorly understood.
Alcohol Appetite
The most striking-and recently identified-inducer of circulating FGF21 in humans is ethanol, with 0.9 g/kg increasing total plasma FGF21 levels 40-fold (14) . Even a modest amount of alcohol, two or three drinks in fasted subjects (,0.4 g/kg), increased FGF21 levels 3.4-fold after 2 hours. Furthermore, 3 days of drinking 22.6 beers per day at Oktoberfest raised basal fasting levels more than twofold more than a day after the last drink (15).
This potent induction of FGF21 by alcohol is eyecatching because variants in the KLB gene, which encodes the FGF21 and FGF19 coreceptor b-klotho, were recently associated with levels of voluntary alcohol drinking in humans by two large and independent genome-wide association studies (16, 17) .
Moreover, the rs838133 A allele in FGF21 itself was significantly associated with increased alcohol intake in the Danish Inter99 cohort (18) and in the UK Biobank (19) , suggesting that the KLB association with alcohol drinking may be mediated by FGF21, not FGF19, a gutderived regulator of bile acid synthesis.
In addition, a glucokinase regulatory protein missense variant that was associated with elevated plasma FGF21 levels in a large clinical study (n = 5169) (20) was also linked at genome-wide significance with reduced alcohol intake in subjects from the UK Biobank (17) .
Although the biology of FGF21 can be quite different in rodents in some cases, these human observations are supported by the fact that alcohol intake also elevates FGF21 levels in mice (21) and that FGF21 treatment suppresses murine alcohol drinking via b-klotho in the central nervous system (16, 22) .
Diet Quality
Human FGF21 variants are also associated with increased carbohydrate intake as a percentage of total energy intake (19, 23, 24) , possibly because of an increased preference for dietary sugars (25) . This is noteworthy because circulating FGF21 levels in humans are increased acutely by boluses of glucose (10, 25) , fructose (26) , and sucrose (18) and because treating nonhuman primates with the long-acting FGF21 analog PF-05231023 decreased consumption of sweet saccharin solutions by 80% (22) . In addition, short-term carbohydrate-but not fat-overfeeding (+75% energy for 3 days) increased basal plasma FGF21 levels eightfold (27) , underscoring the connection between carbohydrate intake and increased FGF21 production in man.
Supporting these observations, FGF21-overexpressing and FGF21-treated mice consumed less sugar (22, 25) , whereas FGF21 knockout animals ate twice as much sucrose as wild-type animals (25) . Interestingly, in the mouse, sugar-evoked FGF21 production was exclusively from the liver and was mediated by the conserved transcription factor ChREBP (25, 28, 29) , an essential player in the transcriptional response to sugars in a range of organisms, including Drosophila (30).
Body Weight
Circulating FGF21 levels also rise in humans during subchronic and chronic energy excess and are correlated with increasing amounts of intrahepatic fat (13). Although FGF21 variants are only weakly associated with body mass index (GIANT Consortium), body mass index is positively correlated with circulating FGF21 levels (11, 12) ; in addition, clinical FGF21 analogs and mimetics (PF-05231023, LY2405319, AMG-876, BFKB8448A) modestly-but consistently-reduced body weight (2% to 4.2%) in humans and nonhuman primates over short time scales (31) , most likely in part by reducing food intake (32) .
Cholesterol, Triglyceride, and Cardiovascular Disease
In humans, FGF21 variants are also associated with changes in low-density lipoprotein cholesterol and triglyceride levels (Global Lipids Genetics Consortium). In recent clinical trials, this association was supported by dramatic and consistent 50% decreases in triglyceride levels and 20% to 40% decreases in low-density lipoprotein cholesterol levels observed with FGF21 analog treatment (31) . In addition, FGF21-based therapies increased high-density lipoprotein cholesterol levels in humans by 20% to 60% (PF-05231023, LY2405319, AMG-876, and BFKB8448A) (31, 33) .
Some of these salutary lipid changes may be mediated by the hormone adiponectin, which is dramatically increased in humans (90% to 246%) by FGF21-based therapeutics and stimulates lipid oxidation and sequestration in adipose tissue (31, 34) . These data are further supported by rodent evidence suggesting that FGF21 also potently elicits adiponectin production in mice (35) . FGF21 analogs also tend to increase ketone body levels (31), consistent with the key role described for FGF21 in promoting hepatic lipid oxidation in mice (36, 37) .
In addition to their associations with atherogenic lipid levels, FGF21 variants have been linked to changes in blood pressure (19) and have been associated with increased risk of stroke and large and small vessel disease, but not cardioembolic stroke, in humans (38, 39) . Interestingly, FGF21 analogs can elevate blood pressure level and heart rate, although the mechanism underlying this effect is unclear (40).
Glycemia
Although discovered as an antidiabetic factor in rodents, FGF21 analogs do not have major effects on glycemia in humans (31) . However, they do improve markers of insulin sensitivity and antidiabetic adipokines, suggesting that longer treatment might improve glucose control. Notably, glucagon has been shown to increase circulating FGF21 levels in humans, and it will be interesting to see whether glycemia-evoked changes in hepatic ChREBP activity contribute to this effect (41) .
Bone
In mice, FGF21 reduced bone mass in some (42), but not all, studies (43) . Moreover, no change in bone mineral content occurred in obese nonhuman primates treated with the long-acting FGF21 analog PF-05231023 (31). Nevertheless, twice-weekly dosing of PF-05231023 modestly increases a marker of bone resorption (i.e., CTX-1) in humans and decreases markers of bone formation (i.e., osteocalcin, P1NP, and BSAP), though these findings are complicated by concurrent weight loss, which has similar effects on bone biomarkers (31) . With once-weekly dosing of PF-05231023, however, there is no change in body weight; however, there are small reductions in P1NP and osteocalcin without an increase in CTX-1. This suggests that FGF21 may have a direct effect on bone in humans, and it will be of great interest to see how the other FGF21 therapeutics currently in clinical development affect these end points.
Tissue Stress
FGF21 is also increased in humans in response to tissue stress. For instance, plasma FGF21 levels are elevated in patients with mitochondrial myopathies (44, 45) . FGF21 levels are also increased by acute exercise (46) as well as dietary protein dilution (47) , in the latter case via members of the ATF transcription factor family (48, 49) . Interestingly, during tissue stress, FGF21 is coinduced with GDF15, a toxin-induced inhibitor of appetite in rodents, whose metabolic functions have recently attracted widespread attention (44, 50, 51) .
Conclusions
In humans as in rodents, FGF21 exerts diverse effects in multiple tissue types; however, unlike in rodents, these effects may not necessarily be related to a physiological response to fasting. Indeed, despite continued development of FGF21 as a therapeutic for obesity and nonalcoholic steatohepatitis, understanding the nature and cellular mechanisms of its pharmacological-and physiological-actions in humans is an ongoing challenge. It seems likely that one consilient function of FGF21 in primates may be to protect the liver from nutrient overload and attendant stress by several means: (1) promoting fatty acid oxidation; (2) reducing consumption of hepatotoxic carbohydrates (i.e., alcohol and fructose); and (3) reducing ectopic lipid storage in hepatocytes by promoting adiponectin production and lipid sequestration in adipose tissue.
However, many outstanding questions remain. In particular, there is a need to fully delineate the sites of FGF21 action in man and understand how modified FGF21 analogs can elicit ostensibly central nervous system-dependent phenotypes, despite probable difficulties in crossing the blood-brain barrier. This undertaking will be essential to understanding the likely safety profile of FGF21-based medicines. A more refined understanding of how FGF21 is regulated by different physiological stimuli is also a priority, aided by new reagents that take the proteolytic inactivation of plasma FGF21 (52) (53) (54) (55) into account, a current problem that leads to discrepant results between different FGF21 enzyme-linked immunosorbent assay kits (18 
